AVAI BIO (AVAI) Stock News

Avant Technologies (OTCQB:AVAI) and Ainnova Tech are finalizing a prototype of their proprietary automated retinal camera through their joint venture, Ai-nova Acquisition Corp (AAC). The new device aims to disrupt the market with a significantly lower cost compared to existing fundus cameras while offering seamless integration with Ainnova's Vision AI software platform. The Vision AI platform can detect early markers of various diseases including diabetic retinopathy, glaucoma, macular edema, age-related macular degeneration, cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease. The automated camera will capture and upload images to the Vision AI platform, which generates risk reports within seconds. AAC holds global licensing rights for developing, maintaining, and marketing Ainnova's technology portfolio.

Avant Technologies (OTCQB: AVAI) has signed a non-binding letter of intent (LOI) for a business combination with Ainnova Tech, a healthcare technology company specializing in AI-powered early disease detection. The merger would integrate 100% of Ainnova's equity into the combined public company, with the final structure pending due diligence. The companies expect to announce a definitive agreement by early next quarter, subject to various approvals. This merger builds on their existing joint venture through Ai-nova Acquisition Corp., formed in late 2024. The timing aligns with their upcoming FDA pre-submission meeting in July regarding Ainnova's Vision AI platform for diabetic retinopathy detection. The merger aims to streamline technology commercialization and enhance shareholder value by combining their AI healthcare capabilities.

Avant Technologies (OTCQB: AVAI) and Ainnova Tech are finalizing a prototype of a low-cost automated retinal camera that integrates with Ainnova's Vision AI platform. The camera will automatically capture and upload retinal images to the AI platform, which generates risk reports within seconds. The Vision AI software can detect multiple diseases including diabetic retinopathy, glaucoma, macular edema, cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease. While Vision AI currently works with any fundus camera, this proprietary device aims to provide a cost-effective, user-friendly solution for market entry and capture. The development is being conducted through Ai-nova Acquisition Corp. (AAC), a joint venture between Avant and Ainnova, which holds global licensing rights for Ainnova's technology portfolio.

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech are exploring the integration of early dementia detection into Ainnova's Vision AI platform. The companies are considering either licensing or acquiring a patented technology that uses AI algorithms and hardware for dementia detection through a 5-minute blood test.

The Vision AI platform currently employs 4 integrated algorithms to assess risks for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease using retinal images, blood pressure, and lab test data. The system utilizes an automated, low-cost retinal imaging device for comprehensive preventive risk screening.

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech are in negotiations to license or acquire patented early disease detection technology from an international healthcare innovation company. The potential deal aims to enhance preventive health reporting capabilities and disease detection correlation without requiring complete patient data. The companies are building their technology portfolio through their AI-driven Vision AI platform, with a focus on making early disease detection more accessible and affordable. They have already integrated four algorithms through exclusive licensing and view retinal examination as a new vital sign, combined with laboratory tests and patient data for comprehensive health reporting.

Avant Technologies (OTCQB:AVAI) and its partner Ainnova Tech announced that Ainnova will sponsor and participate in the 2025 Healthcare Innovation Summit in Mexico City. Ainnova's CEO, Vinicio Vargas, will be a featured speaker presenting on "Preventative Healthcare with Artificial Intelligence: Breaking the Status Quo."

The companies have formed Ai-nova Acquisition Corp. (AAC), which holds global licensing rights for Ainnova's technology portfolio, including its Vision AI platform and retinal cameras. The Healthcare Innovation Summit Series is a global event bringing together key healthcare stakeholders to discuss healthcare transformation, focusing on system optimization, digital transformation, diagnostic technology, and infrastructure.

Avant Technologies (OTCQB: AVAI) and Ainnova Tech have entered acquisition negotiations to strengthen their position in the AI-driven healthcare industry. The companies, which formed Ai-nova Acquisition Corp (AAC) six months ago, are looking to consolidate before their FDA pre-submission meeting in July 2025 regarding clinical trials for the Vision AI platform in diabetic retinopathy detection.

AAC currently holds worldwide licensing rights for Ainnova's technology portfolio, which includes the Vision AI platform and retinal cameras. The proposed merger aims to streamline the advancement of their technology to market and enhance resource utilization. The companies believe consolidating operations will facilitate their FDA interactions and accelerate their entry into the U.S. market.

Avant Technologies (OTCQB:AVAI) and its partner Ainnova Tech have initiated the design of their clinical trial protocol for the Vision AI platform, aimed at early detection of diabetic retinopathy. The company has hired an ophthalmologist to assist in drafting the protocol requirements for their CRO, Fortrea. The pre-submission meeting with the FDA is expected in mid-May 2025.

Ai-nova Acquisition Corp. (AAC), formed through the Avant-Ainnova partnership, holds global licensing rights for Ainnova's technology portfolio. The FDA pre-submission program will help determine the regulatory pathway, including patient and clinic requirements for clinical data generation, and help Avant establish a precise budget for the FDA process.

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have secured a pre-submission meeting with the FDA scheduled for July 7, 2025. The meeting will discuss their planned clinical trial for the Vision AI platform, designed for early detection of diabetic retinopathy. Through Ai-nova Acquisition Corp. (AAC), formed by the partnership, the companies aim to determine crucial trial parameters including the number of clinical sites, patient count, and protocol approval.

The meeting represents a significant step toward obtaining FDA 510(k) clearance for U.S. market entry. AAC holds worldwide licensing rights for Ainnova's technology portfolio, making successful FDA interactions crucial for commercialization in the United States market.